Biotech Investors & VC Firms in Switzerland

92 firms in this list, with a median first check of $540K. 23 of them lead rounds. Generated from verified public data and updated continuously.

Fund	FoxScore	HQ	Invests	Stage	Check	CRM
VE Vesalius Biocapital III Partners SàRL CSGGMLCW12 people	88🔒	Contern	LU	Seed–Late Stage	$10.8M	+ Add to CRM
GR Green Generation Fund Follows rounds	88🔒	Berlin	DE	Pre-Seed–Series A	$540K – $2.7M	+ Add to CRM
SI Sirius Venture Partners GmbH FVMBASJS8 people	88🔒	Wiesbaden	DE	Seed–Growth	$540K – $5.4M	+ Add to CRM
ZÜ Zühlke Ventures PGSW2 people · Follows rounds	88🔒	Zurich	CH	Pre-Seed–Series A	$165K – $275K	+ Add to CRM
RT RTW Investments L.P. NYGMJKLC16 people	88🔒	New York	US	Seed–Series A	—	+ Add to CRM
RO Roche Venture Fund AHDESGCN6 people	88🔒	Basel	CH	Seed–Growth	$648K – $3.2M	+ Add to CRM
OC OCCIDENT MPPSCBPS4 people	88🔒	Munich	DE	Pre-Seed–Series A	—	+ Add to CRM
BL BlueOcean Ventures EDFSSHTZ6 people · Leads rounds	88🔒	Geneva	CH	Pre-Seed–Series A	$270K – $1.4M	+ Add to CRM
EX Exelixis Capital GDMDSD3 people	88🔒	Zürich	CH	—	—	+ Add to CRM
VI VIVES Partners AVPDSSYV4 people	88🔒	Wavre	BE	Pre-Seed–Series B	$108K – $7.6M	+ Add to CRM
ED EDB Investments CKCLCGJO11 people	88🔒	Singapore	SG	Seed–Late Stage	$12M – $400M	+ Add to CRM
P5 P53 Invest SSLMKSØS5 people	88🔒	Stavanger	NO	Seed–Series A	—	+ Add to CRM
HB HBM Partners DDDUFDFD5 people	88🔒	Zug	CH	Pre-Seed–Late Stage	$5M – $50M	+ Add to CRM
SE Sectoral Asset Management MSFBMMCP8 people	88🔒	Montreal	CA	Series A–Late Stage	—	+ Add to CRM
VE Venture TKAHAKAF8 people	88🔒	Zurich	CH	Pre-Seed–Series B	—	+ Add to CRM
4S 4see Ventures DBRB2 people	88🔒	Chêne-Bougeries	CH	Pre-Seed–Series B	$432K – $1.1M	+ Add to CRM
RO Rosetta Capital Ltd. JHKMMFDL7 people	88🔒	Oxford	GB	Series A–Late Stage	—	+ Add to CRM
HE Hermann Hauser Investment DWMHHHJH6 people	88🔒	Innsbruck	AT	Seed–Series A	—	+ Add to CRM
EX Excellis Holding AELL2 people · Follows rounds	88🔒	Torino	IT	Pre-Seed–Series A	—	+ Add to CRM
VE Ventura BioMed Investors AJKR2 people · Follows rounds	88🔒	Munich	DE	Seed–Series A	$1.1M – $5.5M	+ Add to CRM
NG NGN Capital JCKAPJKJ6 people	88🔒	New York	US	Series A–Late Stage	—	+ Add to CRM
AL Alpina Partners FSPS2 people · Leads rounds	88🔒	Munich	DE	Series A–Late Stage	$635K – $2.5M	+ Add to CRM
BI BioScience Ventures Group AG NWMH2 people	88🔒	Munich	DE	Pre-Seed–Series A	$220K – $550K	+ Add to CRM
CA CARMA FUND CLMRCSMM4 people	88🔒	Munich	DE	Pre-Seed–Series A	—	+ Add to CRM

Vesalius Biocapital III Partners SàRL

ConternSeed–Late Stage$10.8M

CSGGMLCW12 people

Green Generation Fund

BerlinPre-Seed–Series A$540K – $2.7M

Sirius Venture Partners GmbH

WiesbadenSeed–Growth$540K – $5.4M

FVMBASJS8 people

Zühlke Ventures

ZurichPre-Seed–Series A$165K – $275K

PGSW2 people

RTW Investments L.P.

New YorkSeed–Series A

NYGMJKLC16 people

Roche Venture Fund

BaselSeed–Growth$648K – $3.2M

AHDESGCN6 people

OCCIDENT

MunichPre-Seed–Series A

MPPSCBPS4 people

BlueOcean Ventures

GenevaPre-Seed–Series A$270K – $1.4M

EDFSSHTZ6 people

Exelixis Capital

Zürich

GDMDSD3 people

VIVES Partners

WavrePre-Seed–Series B$108K – $7.6M

AVPDSSYV4 people

EDB Investments

SingaporeSeed–Late Stage$12M – $400M

CKCLCGJO11 people

P53 Invest

StavangerSeed–Series A

SSLMKSØS5 people

HBM Partners

ZugPre-Seed–Late Stage$5M – $50M

DDDUFDFD5 people

Sectoral Asset Management

MontrealSeries A–Late Stage

MSFBMMCP8 people

Venture

ZurichPre-Seed–Series B

TKAHAKAF8 people

4see Ventures

Chêne-BougeriesPre-Seed–Series B$432K – $1.1M

DBRB2 people

Rosetta Capital Ltd.

OxfordSeries A–Late Stage

JHKMMFDL7 people

Hermann Hauser Investment

InnsbruckSeed–Series A

DWMHHHJH6 people

Excellis Holding

TorinoPre-Seed–Series A

AELL2 people

Ventura BioMed Investors

MunichSeed–Series A$1.1M – $5.5M

AJKR2 people

NGN Capital

New YorkSeries A–Late Stage

JCKAPJKJ6 people

Alpina Partners

MunichSeries A–Late Stage$635K – $2.5M

FSPS2 people

BioScience Ventures Group AG

MunichPre-Seed–Series A$220K – $550K

NWMH2 people

CARMA FUND

MunichPre-Seed–Series A

CLMRCSMM4 people

Data sourced from public filings and firms' own websites — see our methodology.